Unwrapping microcomputed tomographic images for measuring cortical osteolytic lesions in the 5T2 murine model of myeloma treated by bisphosphonate

Micron

Volumn 68, Issue , 2015, Pages 107-114

  NDiaye, Mambaye ^a   Libouban, Hélène ^a   Aguado, Eric ^a,b   Bouvard, Béatrice ^a,c   Audran, Maurice ^a,c   Chappard, Daniel ^a  

^a UNIV Angers   (France)

^b LUNAM UNIVERSITÉ   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Bisphosphonate; Cortical bone; MicroCT; Myeloma; Osteolysis

Indexed keywords

COMPUTERIZED TOMOGRAPHY; MAMMALS; POROSITY;

BISPHOSPHONATES; CORTICAL BONE; MICRO CT; MYELOMA; OSTEOLYSIS;

BONE;

MURINAE;

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ANIMAL; DISEASE MODEL; DRUG MONITORING; EVALUATION STUDY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MULTIPLE MYELOMA; OSTEOLYSIS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG MONITORING; MICE; MULTIPLE MYELOMA; OSTEOLYSIS; TREATMENT OUTCOME; X-RAY MICROTOMOGRAPHY;

EID: 84910650339     PISSN: 09684328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micron.2014.10.001     Document Type: Article

References (47)

1. Bataille R. Management of myeloma with bisphosphonates. N. Engl. J. Med. 1996, 334:529-530.
2. Bataille R., Chappard D., Marcelli C., Dessauw P., Baldet P., Sany J., Alexandre C. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest. 1991, 88:62-66.
3. Bataille R., Chappard D., Marcelli C., Dessauw P., Sany J., Baldet P., Alexandre C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J. Clin. Oncol. 1989, 7:1909-1914.
4. Bauerle T., Hillengass J., Fechtner K., Zechmann C.M., Grenacher L., Moehler T.M., Christiane H., Wagner-Gund B., Neben K., Kauczor H.U., Goldschmidt H., Delorme S. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 2009, 252:477-485.
5. Belch A.R., Bergsagel D.E., Wilson K., O'Reilly S., Wilson J., Sutton D., Pater J., Johnston D., Zee B. Effect of daily etidronate on the osteolysis of multiple myeloma. J. Clin. Oncol. 1991, 9:1397-1402.
6. Benameur T., Chappard D., Fioleau E., Andriantsitohaina R., Martinez M.C., Clere N., Marchand-Libouban H. Plasma cells release membrane microparticles in a mouse model of multiple myeloma. Micron 2013, 54-55:75-81.
7. Berenson J.R. The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma. Rev. Contemp. Pharmacother. 1998, 9:195-203.
8. Berenson J.R., Rosen L.S., Howell A., Porter L., Coleman R.E., Morley W., Dreicer R., Kuross S.A., Lipton A., Seaman J.J. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001, 91:1191-1200.
9. Body J.J. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003, 97:859-865.
10. Chappard D. Technical aspects: how do we best prepare bone samples for proper histological analysis?. Bone Cancer: Progression and Therapeutic Approaches 2009, 203-210. Acad. Press, Elsevier Inc., London. D. Heymann (Ed.).
11. Chappard D., Petitjean M., Alexandre C., Vico L., Minaire P., Riffat G. Cortical osteoclasts are less sensitive to etidronate than trabecular osteoclasts. J. Bone Miner. Res. 1991, 6:673-680.
12. Croese J.W., Vas Nunes C.M., Radl J., van den Enden-Vieveen M.H., Brondijk R.J., Boersma W.J. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br. J. Cancer 1987, 56:555-560.
13. Croucher P.I., De Raeve H., Perry M.J., Hijzen A., Shipman C.M., Lippitt J., Green J., Van Marck E., Van Camp B., Vanderkerken K. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. 2003, 18:482-492.
14. Dallas S.L., Babatunde B.O., Oyajobi O., Dallas M.R., Boyce B.F., Bauss F., Radl J., Mundy G.R. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999, 93:1697-1706.
15. Dempster D.W., Compston J.E., Drezner M.K., Kanis J.A., Malluche H. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2013, 28:2-17.
16. Dimopoulos M., Terpos E., Comenzo R.L., Tosi P., Beksac M., Sezer O., Siegel D., Lokhorst H., Kumar S., Rajkumar S.V., Niesvizky R., Moulopoulos L.A., Durie B.G., Imwg International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009, 23:1545-1556.
17. Dinter D.J., Neff W.K., Klaus J., Bohm C., Hastka J., Weiss C., Schoenberg S.O., Metzgeroth G. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy. Ann. Hematol. 2009, 88:457-464.
18. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296:235-242.
19. El Kadmiri O., Masmoudi L. An omnidirectional image unwrapping approach. International Conference on Multimedia Computing and Systems (ICMCS) 2011, 1-4.
20. Green J.R., Muller K., Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 1994, 9:745-751.
21. Healy C.F., Murray J.G., Eustace S.J., Madewell J., O'Gorman P.J., O'Sullivan P. Multiple myeloma: a review of imaging features and radiological techniques. Bone Marrow Res. 2011, 2011:583439.
22. Kanis J.A., McCloskey E.V. Bisphosphonates in multiple myeloma. Cancer 2000, 88:3022-3032.
23. Kavanagh K.L., Guo K., Dunford J.E., Wu X., Knapp S., Ebetino F.H., Rogers M.J., Russell R.G., Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7829-7834.
24. Kepucka E., Gurcan I., Temizel A. Fast Omnidirectional Image Unwrapping on GPU, Euromicro International Conference on Parallel, Distributed and Network-Based Computing (WIP) 2012, WIP.
25. Labrinidis A., Hay S., Liapis V., Findlay D.M., Evdokiou A. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. Int. J. Cancer 2010, 127:345-354.
26. Lentzsch S., Gries M., Janz M., Bargou R., Dorken B., Mapara M.Y. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003, 101:3568-3573.
27. Libouban H., Moreau M.F., Baslé M.F., Bataille R., Chappard D. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. Bone 2003, 33:283-292.
28. Libouban H., Moreau M.F., Baslé M.F., Bataille R., Chappard D. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse. Biochem. Biophys. Res. Commun. 2004, 316:859-866.
29. Machado M., Cruz L.S., Tannus G., Fonseca M. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin. Ther. 2009, 31:962-979.
30. Mahindra A., Pozzi S., Raje N. Clinical trials of bisphosphonates in multiple myeloma. Clin. Adv. Hematol. Oncol. 2012, 10:582-587.
31. Merlotti D., Gennari L., Martini G., Valleggi F., De Paola V., Avanzati A., Nuti R. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. J. Bone Miner. Res. 2007, 22:1510-1517.
32. Mhaskar R., Redzepovic J., Wheatley K., Camara Clark O.A., Miladinovic B., Glasmacher A., Kumar A., Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst. Rev. 2012, 5:CD003188.
33. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., Mangood A., Russell R.G.G., Ebetino F.H. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
34. Nyangoga H., Blouin S., Libouban H., Baslé M.F., Chappard D. A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat. Microsc. Res. Tech. 2010, 73:733-740.
35. Pataki A., Muller K., Green J.R., Ma Y.F., Li Q.N., Jee W.S. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before during, and after treatment. Anat. Rec. 1997, 249:458-468.
36. Pearse R.N., Sordillo E.M., Yaccoby S., Wong B.R., Liau D.F., Colman N., Michaeli J., Epstein J., Choi Y. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11581-11586.
37. Potúček I. Omni-Directional Image Processing for Human Detection and Tracking 2006, Brno University of Technology, Czech Republic, (PhD Thesis).
38. Quattrocchi C.C., Dell'Aia P., Errante Y., Occhicone F., Longo D., Virzì V., Tonini G., Napoli N., Santini D., Beomonte Zobel B. Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases. J. Bone Oncol. 2012, 1:24-29.
39. Radl J., Croese J.W., Zurcher C., van den Enden-Vieveen M.H., Brondijk R.J., Kazil M., Haaijman J.J., Reitsma P.H., Bijvoet O.L. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 1985, 55:1030-1040.
40. Roodman G.D. Pathogenesis of myeloma bone disease. Leukemia 2009, 23:435-441.
41. Schenk R., Eggli P., Fleisch H., Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif. Tissue Int. 1986, 38:342-349.
42. Strauss O., Comby F. Opérations morphologiques floues à noyaux variables pour images omnidirectionnelles à point de vue unique. Traitement du Signal 2005, 22:453-468.
43. Terpos E., Dimopoulos M.A., Berenson J. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Crit. Rev. Oncol. Hematol. 2011, 77:S13-S23.
44. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., Shaughnessy J.D. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 2003, 349:2483-2494.
45. Turek J., Ebetino F.H., Lundy M.W., Sun S., Kashemirov B.A., McKenna C.E., Gallant M.A., Plotkin L.I., Bellido T., Duan X., Triffitt J.T., Russell R.G., Burr D.B., Allen M.R. Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits. Calcif. Tissue Int. 2012, 90:202-210.
46. Vanderkerken K., Asosingh K., Croucher P., Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol. Rev. 2003, 194:196-206.
47. Vanderkerken K., Asosingh K., Willems A., De Raeve H., Couck P., Gorus F., Croucher P., Van Camp B. The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol. Med. 2005, 113:191-205.